| Year |
Citation |
Score |
| 2020 |
Alhajala HS, Markley JL, Kim JH, Al-Gizawiy MM, Schmainda KM, Kuo JS, Chitambar CR. The cytotoxicity of gallium maltolate in glioblastoma cells is enhanced by metformin through combined action on mitochondrial complex 1. Oncotarget. 11: 1531-1544. PMID 32391122 DOI: 10.18632/Oncotarget.27567 |
0.334 |
|
| 2019 |
Al-Gizawiy M, Wujek R, Prah M, Knipstein J, Alhajala H, Doan N, Molino S, Mirza S, Chitambar C, Schmainda K. THER-12. NOVEL IRON-TARGETED THERAPY IS HIGHLY EFFECTIVE IN TREATMENT-RESISTANT HIGH-GRADE GLIOMA IN VIVO Neuro-Oncology. 21: ii116-ii116. DOI: 10.1093/Neuonc/Noz036.219 |
0.329 |
|
| 2019 |
Molino S, Al-Gizawiy M, Knipstein J, Schmainda K, Chitambar C. HGG-05. GALLIUM MALTOLATE AS TREATMENT IN PEDIATRIC GLIOMA Neuro-Oncology. 21: ii87-ii87. DOI: 10.1093/Neuonc/Noz036.099 |
0.331 |
|
| 2018 |
Alhajala HS, Nguyen HS, Shabani S, Best B, Kaushal M, Al-Gizawiy MM, Erin Ahn EY, Knipstein JA, Mirza S, Schmainda KM, Chitambar CR, Doan NB. Irradiation of pediatric glioblastoma cells promotes radioresistance and enhances glioma malignancy genome-wide transcriptome changes. Oncotarget. 9: 34122-34131. PMID 30344926 DOI: 10.18632/Oncotarget.26137 |
0.406 |
|
| 2018 |
Doan NB, Nguyen HS, Alhajala HS, Jaber B, Al-Gizawiy MM, Ahn EE, Mueller WM, Chitambar CR, Mirza SP, Schmainda KM. Identification of radiation responsive genes and transcriptome profiling via complete RNA sequencing in a stable radioresistant U87 glioblastoma model. Oncotarget. 9: 23532-23542. PMID 29805753 DOI: 10.18632/Oncotarget.25247 |
0.379 |
|
| 2018 |
Chitambar CR, Al-Gizawiy MM, Alhajala HS, Pechman KR, Wereley JP, Wujek R, Clark PA, Kuo JS, Antholine WE, Schmainda KM. Gallium Maltolate Disrupts Tumor Iron Metabolism and Retards the Growth of Glioblastoma by Inhibiting Mitochondrial Function and Ribonucleotide Reductase. Molecular Cancer Therapeutics. PMID 29592883 DOI: 10.1158/1535-7163.Mct-17-1009 |
0.473 |
|
| 2018 |
Al-Gizawiy M, Robert W, Alhajala H, Cobb J, Prah M, Mirza S, Chitambar C, Schmainda K. EXTH-48. ORAL GALLIUM MALTOLATE IMPAIRS TUMOR GROWTH AND EXTENDS DISEASE-SPECIFIC SURVIVAL IN A XENOGRAFT MODEL OF RECURRENT GBM Neuro-Oncology. 20: vi95-vi95. DOI: 10.1093/Neuonc/Noy148.396 |
0.399 |
|
| 2018 |
Alhajala H, Doan N, Al-Gizawiy M, Knipstein J, Schmainda K, Chitambar C. HGG-14. IRRADIATION OF PEDIATRIC GLIOBLASTOMA CELLS INDUCES DOWNREGULATION OF TUMOR SUPPRESSOR MICRORNA GENES AND UPREGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) Neuro-Oncology. 20: i91-i91. DOI: 10.1093/Neuonc/Noy059.286 |
0.356 |
|
| 2017 |
Doan NB, Alhajala H, Al-Gizawiy MM, Mueller WM, Rand SD, Connelly JM, Cochran EJ, Chitambar CR, Clark P, Kuo J, Schmainda KM, Mirza SP. Acid ceramidase and its inhibitors: a de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency. Oncotarget. 8: 112662-112674. PMID 29348854 DOI: 10.18632/Oncotarget.22637 |
0.398 |
|
| 2017 |
Prah MA, Al-Gizawiy MM, Mueller WM, Cochran EJ, Hoffmann RG, Connelly JM, Schmainda KM. Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics. Journal of Neuro-Oncology. PMID 28900832 DOI: 10.1007/S11060-017-2617-3 |
0.403 |
|
| 2017 |
Doan NB, Nguyen HS, Al-Gizawiy MM, Mueller WM, Sabbadini RA, Rand SD, Connelly JM, Chitambar CR, Schmainda KM, Mirza SP. Acid ceramidase confers radioresistance to glioblastoma cells. Oncology Reports. PMID 28765947 DOI: 10.3892/Or.2017.5855 |
0.384 |
|
| 2017 |
Flister MJ, Tsaih SW, Stoddard A, Plasterer C, Jagtap J, Parchur AK, Sharma G, Prisco AR, Lemke A, Murphy D, Al-Gizawiy M, Straza M, Ran S, Geurts AM, Dwinell MR, et al. Host genetic modifiers of nonproductive angiogenesis inhibit breast cancer. Breast Cancer Research and Treatment. PMID 28567545 DOI: 10.1007/S10549-017-4311-8 |
0.346 |
|
| 2017 |
Doan NB, Nguyen HS, Montoure A, Al-Gizawiy MM, Mueller WM, Kurpad S, Rand SD, Connelly JM, Chitambar CR, Schmainda KM, Mirza SP. Acid ceramidase is a novel drug target for pediatric brain tumors. Oncotarget. 8: 24753-24761. PMID 28445970 DOI: 10.18632/Oncotarget.15800 |
0.46 |
|
| 2017 |
Alhajala HS, Joshi D, Al-Gizawiy MM, Hedlund B, Elford HL, Schmainda KM, Chitambar CR. EXTH-40. TUMOR IRON STATUS SENSITIZES GLIOBLASTOMA CELLS TO THE CYTOTOXICITY OF AN INHIBITOR OF THE IRON-DEPENDENT M2 SUBUNIT OF RIBONUCLEOTIDE REDUCTASE Neuro-Oncology. 19: vi81-vi81. DOI: 10.1093/Neuonc/Nox168.332 |
0.354 |
|
| 2017 |
Al-Gizawiy MM, Wujek RT, Alhajala HS, Doan NB, Knipstein J, Connelly JM, Mirza SP, Chitambar CR, Schmainda KM. TMOD-08. IN VITRO PRE-TREATMENT OF CELL LINES PRODUCES A ROBUST IN VIVO XENOGRAFT MODEL MIMICKING RECURRENT GLIOBLASTOMA Neuro-Oncology. 19: vi256-vi256. DOI: 10.1093/Neuonc/Nox168.1047 |
0.337 |
|
| 2017 |
Al-Gizawiy MM, Doan NB, Wujek RT, Alhajala HS, Mirza SP, Chitambar CR, Schmainda KM. TMOD-09. A PATIENT-DERIVED XENOGRAFT MODEL MIMICKING RECURRENT PEDIATRIC MALIGNANT GLIOMA Neuro-Oncology. 19: iv50-iv50. DOI: 10.1093/Neuonc/Nox083.208 |
0.447 |
|
| 2015 |
Al-Gizawiy M, Prah M, Mueller W, Schmainda K. NIMG-01ADVANCED MR PERFUSION AND DIFFUSION MEASURES DISTINGUISH BETWEEN GLIOMA SUBTYPES Neuro-Oncology. 17: v153.1-v153. DOI: 10.1093/Neuonc/Nov225.01 |
0.375 |
|
| 2015 |
Renu D, Aggarwal P, Cherukuri S, Tata P, Bhat V, Livi C, Rosenberg M, Al-Gizawiy M, Mueller W, Connelly J, Schmainda K, Mirza S. GENO-02INTEGRATED ANALYSIS OF MOLECULAR SUBTYPES IN GLIOBLASTOMA MULTIFORME Neuro-Oncology. 17: v91.2-v91. DOI: 10.1093/Neuonc/Nov215.02 |
0.4 |
|
| 2015 |
Al-Gizawiy M, Pechman K, Lozen A, Wereley J, Chitambar C, Schmainda K. ATPS-02CONTINUOUS ADMINISTRATION OF THE NOVEL IRON-MIMETIC GALLIUM MALTOLATE INHIBITS GLIOMA GROWTHIN VITROANDIN VIVO Neuro-Oncology. 17: v18.2-v18. DOI: 10.1093/Neuonc/Nov204.02 |
0.393 |
|
| 2014 |
Heroux MS, Chesnik MA, Halligan BD, Al-Gizawiy M, Connelly JM, Mueller WM, Rand SD, Cochran EJ, LaViolette PS, Malkin MG, Schmainda KM, Mirza SP. Comprehensive characterization of glioblastoma tumor tissues for biomarker identification using mass spectrometry-based label-free quantitative proteomics. Physiological Genomics. 46: 467-81. PMID 24803679 DOI: 10.1152/Physiolgenomics.00034.2014 |
0.339 |
|
| 2014 |
Prah M, Al-Gizawiy M, Mueller W, Hoffmann R, Schmainda K. NI-65 * DIFFERENTIATING RADIATION EFFECT AND NECROSIS FROM GLIOBLASTOMA WITH DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) MRI Neuro-Oncology. 16: v152-v152. DOI: 10.1093/Neuonc/Nou264.63 |
0.325 |
|
| 2014 |
Al-Gizawiy M, Prah M, Mueller W, LaViolette P, Schmainda K. NI-03 * DSC-MRI MEASURES OF rCBV PREDICT TUMOR CHARACTERISTICS BEYOND STANDARD HISTOPATHOLOGY Neuro-Oncology. 16: v138-v138. DOI: 10.1093/Neuonc/Nou264.3 |
0.43 |
|
| 2013 |
Smeester BA, Al-Gizawiy M, O'Brien EE, Ericson ME, Triemstra JL, Beitz AJ. The effect of electroacupuncture on osteosarcoma tumor growth and metastasis: analysis of different treatment regimens. Evidence-Based Complementary and Alternative Medicine : Ecam. 2013: 387169. PMID 24228059 DOI: 10.1155/2013/387169 |
0.573 |
|
| 2013 |
Pechman KR, Lozen A, Al-Gizawiy M, Schmainda K, Chitambar CR. Abstract 5606: Gallium maltolate inhibits brain tumor volume and blood volume in xenograft model. Cancer Research. 73: 5606-5606. DOI: 10.1158/1538-7445.Am2013-5606 |
0.473 |
|
| 2012 |
Smeester BA, Al-Gizawiy M, Beitz AJ. Effects of different electroacupuncture scheduling regimens on murine bone tumor-induced hyperalgesia: sex differences and role of inflammation. Evidence-Based Complementary and Alternative Medicine : Ecam. 2012: 671386. PMID 23320035 DOI: 10.1155/2012/671386 |
0.562 |
|
| Show low-probability matches. |